{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:02:30Z","timestamp":1791820950815,"version":"4.3.4"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Diabetic kidney disease (DKD) represents one of the most serious microvascular complications associated with diabetes mellitus (DM), and its early diagnosis is crucial for improving prognosis. While fibroblast growth factor 23 (FGF23) has been linked to DKD risk in numerous studies, the existing evidence remains controversial. This study sought to synthesize existing observational data through a systematic review and meta-analysis to clarify the overall association between FGF23 levels and DKD and explore its significance as a potential biomarker.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive search of Cochrane Library, PubMed, Embase, and Web of Science was conducted to identify eligible studies published up to October 23, 2025. We included observational studies that compared FGF23 levels between patients with DKD and non-DKD controls, or evaluated DKD risk. Two researchers independently screened the literature, extracted data, and evaluated methodological quality using the Newcastle\u2013Ottawa Scale (NOS). Statistical analyses were performed with Stata version 15.1. Effect sizes were expressed as standardized mean differences (SMDs) and odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Between-study heterogeneity was quantified using the I\u00b2 statistic, and subgroup, sensitivity, and publication bias analyses were carried out.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine eligible studies involving 3,799 participants were included. Meta-analysis indicated that serum FGF23 levels were markedly elevated in patients with DKD compared with those without DKD (SMD\u00a0=\u00a01.144, 95% CI: 0.361 to 1.928, p = 0.004). Although the pooled OR for DKD with high FGF23 levels was 1.136 (95% CI: 0.656 to 1.968), this association was not statistically significant in dichotomous variable analysis (p = 0.649), with substantial heterogeneity across studies (I\u00b2 &amp;gt; 80%). Subgroup analyses indicated that region, control type, publication year, DM type, and DKD stage did not fully explain the observed heterogeneity. Sensitivity analyses confirmed the robustness of the mean difference results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FGF23 levels are associated with the progression of DKD, suggesting that it may reflect metabolic disturbances associated with DKD. Given that the OR analysis did not show statistical significance and heterogeneity was substantial, this association should be considered exploratory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251180089.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1799186","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:21:53Z","timestamp":1779164513000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Fibroblast growth factor 23 levels and the risk of diabetic kidney disease: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Xingjia","family":"Wang","sequence":"first","affiliation":[{"name":"Graduate School, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiameng","family":"Li","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzhuo","family":"Wang","sequence":"additional","affiliation":[{"name":"Graduate School, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Zhu","sequence":"additional","affiliation":[{"name":"Graduate School, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Sun","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, The 2nd Affiliated Hospital of Harbin Medical University","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2007091048","article-title":"The role of inflammatory cytokines in diabetic nephropathy","volume":"19","author":"Navarro-Gonz\u00e1lez","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-S010","article-title":"10. Microvascular complications and foot care: Standards of medical care in diabetes-2018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S011","article-title":"11. Chronic kidney disease and risk management: Standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16224","article-title":"Fibroblast growth factor 23 predicts incident diabetic kidney disease: A 4.6-year prospective study","volume":"27","author":"Liu","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2562996","article-title":"Performance of novel biomarkers for prediction of diabetic kidney disease in patients with diabetes mellitus","volume":"57","author":"Zou","year":"2025","journal-title":"Ann Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.339","article-title":"Mineral metabolism disorders in chronic kidney disease","volume":"305","author":"Kestenbaum","year":"2011","journal-title":"Jama"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0528","article-title":"Fibroblast growth factor 23 and mortality in patients with type 2 diabetes and normal or mildly impaired kidney function","volume":"42","author":"Yeung","year":"2019","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2215","article-title":"Fibroblast growth factor 23 and cause-specific mortality in the general population: The Northern Manhattan Study","volume":"101","author":"Souma","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042376","article-title":"The role of bone-derived hormones in glucose metabolism, diabetic kidney disease, and cardiovascular disorders","volume":"23","author":"Takashi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.07.022","article-title":"Longitudinal evolution of markers of mineral metabolism in patients with CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study","volume":"75","author":"Isakova","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.02840320","article-title":"Klotho in clinical nephrology: Diagnostic and therapeutic implications","volume":"16","author":"Neyra","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2012080865","article-title":"Loss of Klotho contributes to kidney injury by derepression of Wnt\/\u03b2-catenin signaling","volume":"24","author":"Zhou","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz266","article-title":"Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study","volume":"36","author":"De Jong","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2215\/cjn.04530418","article-title":"Effects of dapagliflozin on circulating markers of phosphate homeostasis","volume":"14","author":"de Jong","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-022-03420-0","article-title":"Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial","volume":"55","author":"Triwatana","year":"2023","journal-title":"Int Urol Nephrol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2215\/cjn.06190614","article-title":"Fibroblast growth factor 23 and incident CKD in type 2 diabetes","volume":"10","author":"Isakova","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058007","article-title":"Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1","volume":"8","author":"Lee","year":"2013","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1489676","article-title":"Predictive value of bone metabolism markers in the progression of diabetic kidney disease: a cross-sectional study","volume":"15","author":"Kang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2019.01.008","article-title":"Circulating levels of soluble Klotho and fibroblast growth factor 23 in diabetic patients and its association with early nephropathy","volume":"49","author":"Far\u00edas-Basulto","year":"2018","journal-title":"Arch Med Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1042\/cs20201290","article-title":"Phosphate and fibroblast growth factor 23 in diabetes","volume":"135","author":"van der Vaart","year":"2021","journal-title":"Clin Sci (Lond)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/mnh.0000000000001078","article-title":"Fibroblast growth factor 23 as a risk factor for incident diabetes","volume":"34","author":"de Borst","year":"2025","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B25","unstructured":"Wells\n              GA\n            \n            \n              Shea\n              B\n            \n            \n              O\u2019Connell\n              D\n            \n            \n              Peterson\n              J\n            \n            \n              Welch\n              V\n            \n            \n              Losos\n              M\n            \n          \n          The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses\n          \n          2000"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s42000-023-00464-4","article-title":"An evaluation of both serum Klotho\/FGF-23 and apelin-13 for detection of diabetic nephropathy","volume":"22","author":"Ozdemir","year":"2023","journal-title":"Hormones (Athens)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2016-000142","article-title":"Soluble Klotho and fibroblast growth factor 23 levels in diabetic nephropathy with different stages of albuminuria","volume":"64","author":"Inci","year":"2016","journal-title":"J Investig Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.395446","article-title":"Study of serum fibroblast growth factor 23 as a predictor of endothelial dysfunction among Egyptian patients with diabetic kidney disease","volume":"34","author":"Fayed","year":"2023","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2009.009066","article-title":"Determination of fibroblast growth factor 23","volume":"46","author":"Heijboer","year":"2009","journal-title":"Ann Clin Biochem"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1811","article-title":"Biological variability of plasma intact and C-terminal FGF23 measurements","volume":"97","author":"Smith","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study","volume":"18","author":"Fliser","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"Jama"},{"key":"B33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.phrs.2016.02.015","article-title":"Phosphate and FGF23 in the renoprotective benefit of RAAS inhibition","volume":"106","author":"de Seigneux","year":"2016","journal-title":"Pharmacol Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.649921","article-title":"Aldosterone is positively associated with circulating FGF23 levels in chronic kidney disease across four species, and may drive FGF23 secretion directly","volume":"12","author":"Radloff","year":"2021","journal-title":"Front Physiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3390\/cells12040609","article-title":"FGF23 in chronic kidney disease: Bridging the heart and anemia","volume":"12","author":"Figurek","year":"2023","journal-title":"Cells"},{"key":"B36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/ajh\/hpy142","article-title":"Fibroblast growth factor-23, heart failure risk, and renin-angiotensin-aldosterone-system blockade in hypertension: The MESA Study","volume":"32","author":"Akhabue","year":"2019","journal-title":"Am J Hypertens"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.02680310","article-title":"Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23\/Klotho system","volume":"5","author":"Pri\u00e9","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00199.2012","article-title":"Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse bone","volume":"303","author":"Krieger","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M207872200","article-title":"Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production","volume":"278","author":"Saito","year":"2003","journal-title":"J Biol Chem"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00506.x","article-title":"Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules","volume":"68","author":"Baum","year":"2005","journal-title":"Kidney Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.05.019","article-title":"Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease","volume":"90","author":"Singh","year":"2016","journal-title":"Kidney Int"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/0886022x.2018.1455594","article-title":"Fibroblast growth factor-23 is a strong predictor of insulin resistance among chronic kidney disease patients","volume":"40","author":"Fayed","year":"2018","journal-title":"Ren Fail"},{"key":"B43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12896-018-0449-7","article-title":"FGF23(C-tail) improves diabetic nephropathy by attenuating renal fibrosis and inflammation","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Bio\/Technol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1980.85","article-title":"Renal toxicity of phosphate in rats","volume":"17","author":"Haut","year":"1980","journal-title":"Kidney Int"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021119-034650","article-title":"Regulation and effects of FGF23 in chronic kidney disease","volume":"82","author":"Musgrove","year":"2020","journal-title":"Annu Rev Physiol"},{"key":"B46","article-title":"ASSOCIATION OF FIBROBLAST GROWTH FACTOR 23 WITH MARKERS OF INFLAMMATION AND FIBROSIS IN DIABETIC NEPHROPATHY","volume-title":"Georgian med news","author":"Topchii","year":"2019"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.290","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production","volume":"89","author":"David","year":"2016","journal-title":"Kidney Int"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1172\/jci83470","article-title":"FGF23 signaling impairs neutrophil recruitment and host defense during CKD","volume":"126","author":"Rossaint","year":"2016","journal-title":"J Clin Invest"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.02.025","article-title":"Annexin A1 alleviates kidney injury by promoting the resolution of inflammation in diabetic nephropathy","volume":"100","author":"Wu","year":"2021","journal-title":"Kidney Int"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.938830","article-title":"The emerging role of bone-derived hormones in diabetes mellitus and diabetic kidney disease","volume":"13","author":"Li","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222011196","article-title":"Novel cardiovascular risk factors in patients with diabetic kidney disease","volume":"22","author":"Kourtidou","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/fjc.0000000000001559","article-title":"Hypericin alleviates chronic kidney disease-induced left ventricular hypertrophy by regulation of FGF23-FGFR4 signaling pathway","volume":"83","author":"Liu","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1038\/s41598-017-02068-6","article-title":"FGF23\/FGFR4-mediated left ventricular hypertrophy is reversible","volume":"7","author":"Grabner","year":"2017","journal-title":"Sci Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv421","article-title":"Induction of cardiac FGF23\/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease","volume":"31","author":"Leifheit-Nestler","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.01.024","article-title":"Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease","volume":"107","author":"Fuchs","year":"2025","journal-title":"Kidney Int"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2015.09.002","article-title":"Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy","volume":"22","author":"Grabner","year":"2015","journal-title":"Cell Metab"},{"key":"B57","doi-asserted-by":"publisher","first-page":"H2283","DOI":"10.1152\/ajpheart.00798.2020","article-title":"Fibroblast growth factor 23 (FGF23) induces ventricular arrhythmias and prolongs QTc interval in mice in an FGF receptor 4-dependent manner","volume":"320","author":"Graves","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"H1414","DOI":"10.1152\/ajpheart.00272.2018","article-title":"FGF23 impairs peripheral microvascular function in renal failure","volume":"315","author":"Verkaik","year":"2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00264.2014","article-title":"FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability","volume":"307","author":"Silswal","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.09.004","article-title":"Insulin resistance is associated with fibroblast growth factor-23 in stage 3\u20135 chronic kidney disease patients","volume":"28","author":"Garland","year":"2014","journal-title":"J Diabetes Complic"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1097\/hjh.0b013e328337da1d","article-title":"Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction","volume":"28","author":"Yu","year":"2010","journal-title":"J Hypertens"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.04250510","article-title":"FGF-23 as a predictor of renal outcome in diabetic nephropathy","volume":"6","author":"Titan","year":"2011","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1799186\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:21:57Z","timestamp":1779164517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1799186\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":62,"alternative-id":["10.3389\/fendo.2026.1799186"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1799186","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"article-number":"1799186"}}